Biotek-snakken — September 2025
-
Saniona vælger SAN 2668 som klinisk kandidat. https://saniona.com/newsroom/single-press-release/?slug=saniona-selects-san2668-as-first-in-class-clinical-candidate-for-paediatric-epilepsy
-
"BioNTech Surges 10% On Promising Test Results For Its Cancer Smart Bomb" https://www.investors.com/news/technology/biontech-stock-antibody-drug-conjugate-breast-cancer-dualitybio/
-
Mener ikke denne vigtige https://cantargia.com/en/press-releases/cantargia-granted-important-us-patent-for-nadunolimab
Cantargia nyhed har været nævnt. -
PILA PHARMA: ALL H1 REPORT & INVESTOR INTERVIEWS NOW ONLINE https://cdn.bequoted.com/media/1/d184c8c1-105d-4fee-bed3-d57a0a416c33/Pila_Pharma_Pressrelease_2025-09-08.pdf
-
Novartis køber amerikansk biotekfirma for næsten 9 mia. kr. https://proinvestor.com/investornyt/1359439/novartis-kober-amerikansk-biotekfirma-for-naesten-9-mia-kr
-
Gode nyheder fra Cantargia. https://cantargia.com/en/press-releases/cantargia-closes-the-acquisition-of-can10-by-otsuka
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind